Literature DB >> 22350900

Immunoproteasome-specific inhibitors and their application.

Michael Basler1, Marcus Groettrup.   

Abstract

Immunoproteasomes (IPs) containing the interferon-inducible subunits β1i (LMP2), β2i (MECL-1), and β5i (LMP7) alter proteasomal cleavage preference, optimise the generation of peptide ligands of MHC class I molecules, alter cytokine profile, influence T-helper cell differentiation, and play a role in T-cell survival. Small molecule inhibitors are useful tools for probing the role of the immunoproteasome in immune functions. Here, we describe different methods to characterise immunoproteasome-selective inhibitors. Thereby, we provide the methodology to analyse the specificity and cell permeability of immunoproteasome inhibitors, as well as to functionally investigate immunoproteasome inhibitors in antigen presentation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22350900     DOI: 10.1007/978-1-61779-474-2_27

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  7 in total

1.  Activity-based near-infrared fluorescent probe for LMP7: a chemical proteomics tool for the immunoproteasome in living cells.

Authors:  Lalit Kumar Sharma; Na-Ra Lee; Eun Ryoung Jang; Beilei Lei; Chang-Guo Zhan; Wooin Lee; Kyung-Bo Kim
Journal:  Chembiochem       Date:  2012-07-17       Impact factor: 3.164

2.  No evidence for immunoproteasomes in chicken lymphoid organs and activated lymphocytes.

Authors:  Sonja Erath; Marcus Groettrup
Journal:  Immunogenetics       Date:  2014-11-19       Impact factor: 2.846

3.  Amelioration of autoimmunity with an inhibitor selectively targeting all active centres of the immunoproteasome.

Authors:  Michael Basler; Elmer Maurits; Gerjan de Bruin; Julia Koerner; Herman S Overkleeft; Marcus Groettrup
Journal:  Br J Pharmacol       Date:  2017-11-29       Impact factor: 8.739

4.  Co-inhibition of immunoproteasome subunits LMP2 and LMP7 is required to block autoimmunity.

Authors:  Michael Basler; Michelle M Lindstrom; Jacob J LaStant; J Michael Bradshaw; Timothy D Owens; Christian Schmidt; Elmer Maurits; Christopher Tsu; Herman S Overkleeft; Christopher J Kirk; Claire L Langrish; Marcus Groettrup
Journal:  EMBO Rep       Date:  2018-10-02       Impact factor: 8.807

5.  Structure-Activity Relationships of Noncovalent Immunoproteasome β5i-Selective Dipeptides.

Authors:  Wenhu Zhan; Pradeep K Singh; Yi Ban; Xiaoping Qing; Marie Dominique Ah Kioon; Hao Fan; Quanju Zhao; Rong Wang; George Sukenick; Jane Salmon; J David Warren; Xiaojing Ma; Franck J Barrat; Carl F Nathan; Gang Lin
Journal:  J Med Chem       Date:  2020-10-23       Impact factor: 8.039

6.  Inhibiting the immunoproteasome's β5i catalytic activity affects human peripheral blood-derived immune cell viability.

Authors:  Katrien Pletinckx; Silke Vaßen; Ilka Schlusche; Sonja Nordhoff; Gregor Bahrenberg; Torsten R Dunkern
Journal:  Pharmacol Res Perspect       Date:  2019-06-18

Review 7.  Proteasome, a Promising Therapeutic Target for Multiple Diseases Beyond Cancer.

Authors:  Yu Cao; Huajian Zhu; Ruoyu He; Limin Kong; Jiaan Shao; Rangxiao Zhuang; Jianjun Xi; Jiankang Zhang
Journal:  Drug Des Devel Ther       Date:  2020-10-19       Impact factor: 4.162

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.